Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot RCT of colchicine to prevent graft failure after CABG
ChiCTR2500114519Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of colchicine in coronary arteriosclerosis (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Graft lesion rate at 1 year after surgery. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
colchicine
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2500114519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114519.